File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy

TitleAttenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
Authors
Keywordscardiac shock wave
cardiomyopathy
hypertension
Issue Date31-Oct-2022
PublisherMDPI
Citation
International Journal of Molecular Sciences, 2022, v. 23, n. nil How to Cite?
Abstract

Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy.


Persistent Identifierhttp://hdl.handle.net/10722/337376
ISSN
2023 Impact Factor: 4.9
2023 SCImago Journal Rankings: 1.179
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, Fei-
dc.contributor.authorZhen, Zhe-
dc.contributor.authorSun, Si-Jia-
dc.contributor.authorJiang, Yu-
dc.contributor.authorLiang, Wei-Hao-
dc.contributor.authorBelau, Markus-
dc.contributor.authorStorz, Rafael-
dc.contributor.authorLiao, Song-Yan-
dc.contributor.authorTse, Hung-Fat -
dc.date.accessioned2024-03-11T10:20:24Z-
dc.date.available2024-03-11T10:20:24Z-
dc.date.issued2022-10-31-
dc.identifier.citationInternational Journal of Molecular Sciences, 2022, v. 23, n. nil-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/10722/337376-
dc.description.abstract<p>Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy.<br></p>-
dc.languageeng-
dc.publisherMDPI-
dc.relation.ispartofInternational Journal of Molecular Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcardiac shock wave-
dc.subjectcardiomyopathy-
dc.subjecthypertension-
dc.titleAttenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy-
dc.typeArticle-
dc.identifier.doi10.3390/ijms232113274-
dc.identifier.scopuseid_2-s2.0-85141841819-
dc.identifier.volume23-
dc.identifier.issuenil-
dc.identifier.eissn1422-0067-
dc.identifier.isiWOS:000881295000001-
dc.identifier.issnl1422-0067-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats